These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 36322572)

  • 21. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Jitender ; Vikram Kumar B; Singh S; Verma G; Kumar R; Mishra PM; Kumar S; Nagaraj SK; Nag J; Joy CM; Nikam B; Singh D; Pooja ; Kalidas N; Singh S; Mumtaz ; Bhardwaj AK; Mankotia DS; Ringe RP; Gupta N; Tripathi S; Mishra RPN
    Vaccine; 2024 Aug; 42(20):126099. PubMed ID: 38981743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
    Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
    Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
    Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly TA; Luley EH; Rossi RM; Bator CM; Moustafa IM; Norton EB; Hafenstein SL; Lindner SE; Sutton TC
    Microbiol Spectr; 2024 Mar; 12(3):e0499822. PubMed ID: 38334387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
    Hassan AO; Kafai NM; Dmitriev IP; Fox JM; Smith BK; Harvey IB; Chen RE; Winkler ES; Wessel AW; Case JB; Kashentseva E; McCune BT; Bailey AL; Zhao H; VanBlargan LA; Dai YN; Ma M; Adams LJ; Shrihari S; Danis JE; Gralinski LE; Hou YJ; Schäfer A; Kim AS; Keeler SP; Weiskopf D; Baric RS; Holtzman MJ; Fremont DH; Curiel DT; Diamond MS
    Cell; 2020 Oct; 183(1):169-184.e13. PubMed ID: 32931734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
    Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern.
    O'Neill A; Mantri CK; Tan CW; Saron WAA; Nagaraj SK; Kala MP; Joy CM; Rathore APS; Tripathi S; Wang LF; St John AL
    EBioMedicine; 2024 Jan; 99():104924. PubMed ID: 38113758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
    Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
    Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Li L; Honda-Okubo Y; Baldwin J; Bowen R; Bielefeldt-Ohmann H; Petrovsky N
    Vaccine; 2022 May; 40(23):3182-3192. PubMed ID: 35465982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
    Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Honda-Okubo Y; Bowen R; Barker M; Bielefeldt-Ohmann H; Petrovsky N
    Vaccine; 2023 Nov; 41(48):7116-7128. PubMed ID: 37863669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
    Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
    Front Immunol; 2021; 12():729189. PubMed ID: 34603303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
    Kuo TY; Lien CE; Lin YJ; Lin MY; Wu CC; Tang WH; Campbell JD; Traquina P; Chuang YS; Liu LT; Cheng J; Chen C
    J Infect Dis; 2022 Nov; 226(9):1562-1567. PubMed ID: 35451470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques.
    McMahan K; Wegmann F; Aid M; Sciacca M; Liu J; Hachmann NP; Miller J; Jacob-Dolan C; Powers O; Hope D; Wu C; Pereira J; Murdza T; Mazurek CR; Hoyt A; Boon ACM; Davis-Gardner M; Suthar MS; Martinot AJ; Boursiquot M; Cook A; Pessaint L; Lewis MG; Andersen H; Tolboom J; Serroyen J; Solforosi L; Costes LMM; Zahn RC; Barouch DH
    Nature; 2024 Feb; 626(7998):385-391. PubMed ID: 38096903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Pal R; Ferrari MG; Honda-Okubo Y; Wattay L; Caple J; Navarrete J; Andersen H; Petrovsky N
    Vaccine; 2024 Feb; 42(5):1122-1135. PubMed ID: 38262808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals.
    Ye ZW; Ong CP; Tang K; Fan Y; Luo C; Zhou R; Luo P; Cheng Y; Gray VS; Wang P; Chu H; Chan JF; To KK; Chen H; Chen Z; Yuen KY; Ling GS; Yuan S; Jin DY
    Cell Mol Immunol; 2022 May; 19(5):588-601. PubMed ID: 35352010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
    Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H
    Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.